I
Innocare
A Chinese biopharmaceutical company that develops treatment for cancer and autoimmune diseases
About Innocare
InnoCare Pharma is a leading biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and first-in-class drugs for the treatment of cancer and autoimmune diseases. The company operates in the highly specialized field of oncology and immunology, focusing on innovative therapies that address unmet medical needs. InnoCare serves a global market, with a particular emphasis on the U.S. and China, where it conducts extensive clinical trials and research activities.
The company's business model is built around a fully integrated biopharmaceutical platform that encompasses all stages of the drug development cycle. This includes drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing, quality control, and commercialization. By maintaining all these functions in-house, InnoCare enhances operational efficiency and ensures high-quality standards throughout the development process.
InnoCare generates revenue through the commercialization of its proprietary drug candidates, licensing agreements, and partnerships with other pharmaceutical companies. The company has a strong pipeline of drug candidates, including ICP-192, a highly selective pan FGFR inhibitor targeting multiple solid tumors with FGFR gene aberrations, which has received approval from the U.S. FDA for clinical investigations.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
Open roles
Innocare in the Haidian ecosystem
The Innocare office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
CCB International
Vivo Capital
Loyal Valley Capital- JCJianxin Capital
Source: Dealroom Talent Intelligence.
Patents
48 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Innocare on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
InnoCare and Eli Lilly strike research collaboration worth up to $3.35B
